A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.

开始日期2021-09-09

申办/合作机构

The University of Texas MD Anderson Cancer Center

100 项与 IACS-6274 相关的临床结果

登录后查看更多信息

100 项与 IACS-6274 相关的转化医学

登录后查看更多信息

100 项与 IACS-6274 相关的专利（医药）

登录后查看更多信息

项与 IACS-6274 相关的文献（医药）

Exploration of Targeted Anti-tumor Therapy

Aspirin and the metabolic hallmark of cancer: novel therapeutic opportunities for colorectal cancer

Review

作者: Legge, Danny N. ; Hoskin, Ashley J. ; Vincent, Emma E. ; Williams, Ann C. ; Collard, Tracey J. ; Holt, Amy K.

Aspirin is a well-known nonsteroidal anti-inflammatory drug (NSAID) that has a recognized role in cancer prevention as well as evidence to support its use as an adjuvant for cancer treatment. Importantly there has been an increasing number of studies contributing to the mechanistic understanding of aspirins’ anti-tumour effects and these studies continue to inform the potential clinical use of aspirin for both the prevention and treatment of cancer. This review focuses on the emerging role of aspirin as a regulator of metabolic reprogramming, an essential “hallmark of cancer” required to support the increased demand for biosynthetic intermediates needed for sustained proliferation. Cancer cells frequently undergo metabolic rewiring driven by oncogenic pathways such as hypoxia-inducible factor (HIF), wingless-related integration site (Wnt), mammalian target of rapamycin (mTOR), and nuclear factor kappa light chain enhancer of activated B cells (NF-κB), which supports the increased proliferative rate as tumours develop and progress. Reviewed here, cellular metabolic reprogramming has been identified as a key mechanism of action of aspirin and include the regulation of key metabolic drivers, the regulation of enzymes involved in glycolysis and glutaminolysis, and altered nutrient utilisation upon aspirin exposure. Importantly, as aspirin treatment exposes metabolic vulnerabilities in tumour cells, there is an opportunity for the use of aspirin in combination with specific metabolic inhibitors in particular, glutaminase (GLS) inhibitors currently in clinical trials such as telaglenastat (CB-839) and IACS-6274 for the treatment of colorectal and potentially other cancers. The increasing evidence that aspirin impacts metabolism in cancer cells suggests that aspirin could provide a simple, relatively safe, and cost-effective way to target this important hallmark of cancer. Excitingly, this review highlights a potential new role for aspirin in improving the efficacy of a new generation of metabolic inhibitors currently undergoing clinical investigation.

100 项与 IACS-6274 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期子宫内膜癌	临床1期	美国	The University of Texas MD Anderson Cancer Center	2021-09-09
软骨肉瘤	临床1期	美国	The University of Texas MD Anderson Cancer Center	2021-09-09
透明细胞腺癌	临床1期	美国	The University of Texas MD Anderson Cancer Center	2021-09-09
卵巢高级别浆液性腺癌	临床1期	美国	The University of Texas MD Anderson Cancer Center	2021-09-09
皮肤黑色素瘤	临床1期	美国	The University of Texas MD Anderson Cancer Center	2021-09-09
卵巢透明细胞腺癌	临床1期	美国	The University of Texas MD Anderson Cancer Center	2021-09-09
难治性子宫内膜腺癌	临床1期	美国	The University of Texas MD Anderson Cancer Center	2021-09-09
难治性头颈癌	临床1期	美国	The University of Texas MD Anderson Cancer Center	2021-09-09
难治性黑色素瘤	临床1期	美国	The University of Texas MD Anderson Cancer Center	2021-09-09
晚期恶性实体瘤	临床1期	美国	The University of Texas MD Anderson Cancer Center	2021-05-28